Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

@article{Locklin2007SelectiveTO,
  title={Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.},
  author={Rachel M. Locklin and Ermanno Federici and Belen Espina and Philippa A. Hulley and R. Graham G. Russell and Claire M Edwards},
  journal={Molecular cancer therapeutics},
  year={2007},
  volume={6 12 Pt 1},
  pages={3219-28}
}
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a tumor necrosis factor superfamily member, targets death receptors and selectively kills malignant cells while leaving normal cells unaffected. However, unlike most cancers, many osteosarcomas are resistant to TRAIL. To investigate this resistance, we characterized the response of MG-63 osteosarcoma cells and hPOB-tert osteoblast-like cells to TRAIL and agonist antibodies to death receptor 4 (DR4) and death receptor 5 (DR5). We… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Targets for cancer therapy in childhood sarcomas.

Cancer treatment reviews • 2010
View 13 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Molecular determinants of response to TRAIL in killing of normal and cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2000
View 5 Excerpts
Highly Influenced

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Proceedings of the National Academy of Sciences of the United States of America • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…